Phase 2 open label trial reports safety and efficacy evaluation of repeated intrathecal autologous adipose-derived MSCs in ALS, highlighting cellular therapy potential.
In this Phase 2 open label clinical trial, we aim to evaluate the safety and efficacy of repeated intrathecal autologous adipose-derived mesenchymal stromal cells (MSCs) in people living with ALS.
No takes yet. Share an insight, caveat, or question.
Staff et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: